Decreased counts of blood neutrophils, monocytes, and platelets in human immunodeficiency virus-infected children and young adults treated with diethyldithiocarbamate.
Nineteen young human immunodeficiency virus-infected patients were randomized to receive 400 mg of oral diethyldithiocarbamate (DTC) per m2 or placebo weekly for 12 weeks. Changes in blood CD4+ lymphocytes were not significantly different between groups. However, neutrophil, monocyte, and platelet counts consistently decreased during DTC treatment, suggesting DTC-mediated myelosuppression.
Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee 38105.
J L
JL
Shenep
W T
WT
Hughes
P M
PM
Flynn
P K
PK
Roberson
F G
FG
Behm
G H
GH
Fullen
S G
SG
Kovnar
K P
KP
Guito
T O
TO
Brodkey
D000293:Adolescent; D000328:Adult; D001792:Blood Platelets / Q000187:drug effects*; D018791:CD4 Lymphocyte Count / Q000187:drug effects; D002648:Child; D004050:Ditiocarb / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D015658:HIV Infections / Q000097:blood* / Q000188:drug therapy; D006801:Humans; D018655:Lymphocyte Count / Q000187:drug effects; D008297:Male; D009000:Monocytes / Q000187:drug effects*; D009504:Neutrophils / Q000187:drug effects*; D010976:Platelet Count / Q000187:drug effects
D004050:Ditiocarb